GINKGO BIOWORKS HOLDINGS, INC. (DNA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinDNA / S&P 61.66% / 15.20% |
LoseDNA / S&P -46.80% / 15.00% |
LoseDNA / S&P DNA unavailable / 50.40% |
| 2026-Q10/3 |
LoseDNA / S&P -26.23% / -4.33% |
LoseDNA / S&P -42.44% / 11.30% |
LoseDNA / S&P DNA unavailable / 27.70% |
| 2025-Q40/3 |
LoseDNA / S&P -43.00% / 2.65% |
LoseDNA / S&P -34.11% / 9.00% |
LoseDNA / S&P -46.65% / 13.40% |
| 2025-Q31/3 |
WinDNA / S&P 29.60% / 8.12% |
LoseDNA / S&P -26.57% / 4.61% |
LoseDNA / S&P -52.05% / 13.45% |
| 2025-Q22/3 |
WinDNA / S&P 97.37% / 10.94% |
WinDNA / S&P 14.06% / 4.83% |
LoseDNA / S&P -67.74% / 10.63% |
| 2025-Q11/3 |
LoseDNA / S&P -41.96% / -4.27% |
WinDNA / S&P 8.93% / 4.98% |
LoseDNA / S&P -35.61% / 10.57% |
| 2024-Q41/3 |
WinDNA / S&P 20.49% / 2.41% |
LoseDNA / S&P -9.71% / 5.25% |
LoseDNA / S&P -0.94% / 6.15% |
| 2024-Q30/3 |
LoseDNA / S&P -39.00% / 5.89% |
LoseDNA / S&P -30.81% / 5.89% |
LoseDNA / S&P -76.71% / 6.11% |
| 2024-Q20/3 |
LoseDNA / S&P -71.21% / 4.28% |
LoseDNA / S&P -43.45% / 5.38% |
LoseDNA / S&P -63.64% / 5.12% |
| 2024-Q10/3 |
LoseDNA / S&P -31.36% / 10.56% |
LoseDNA / S&P -46.49% / 5.71% |
LoseDNA / S&P -72.17% / 5.59% |
| 2023-Q40/3 |
LoseDNA / S&P -6.63% / 11.69% |
LoseDNA / S&P -47.36% / 6.81% |
LoseDNA / S&P -78.71% / 7.78% |
| 2023-Q32/3 |
WinDNA / S&P -2.69% / -3.27% |
LoseDNA / S&P -40.33% / 7.52% |
WinDNA / S&P 2209.17% / -5.03% |
| 2023-Q22/3 |
WinDNA / S&P 39.85% / 8.74% |
LoseDNA / S&P -39.54% / 9.50% |
WinDNA / S&P 2297.10% / -8.57% |
| 2023-Q11/3 |
LoseDNA / S&P -21.30% / 7.50% |
LoseDNA / S&P -10.99% / 10.77% |
WinDNA / S&P 2837.65% / -15.69% |
| 2022-Q41/3 |
LoseDNA / S&P -45.83% / 7.56% |
WinDNA / S&P 52.21% / 11.88% |
LoseDNA / S&P DNA unavailable / -17.99% |
| 2022-Q32/3 |
WinDNA / S&P 31.09% / -4.88% |
WinDNA / S&P 167.43% / 13.47% |
LoseDNA / S&P DNA unavailable / -1.41% |
| 2022-Q21/3 |
LoseDNA / S&P -40.94% / -16.10% |
WinDNA / S&P 305.08% / 13.71% |
LoseDNA / S&P DNA unavailable / 11.04% |
| 2022-Q10/3 |
LoseDNA / S&P -51.50% / -4.60% |
LoseDNA / S&P DNA unavailable / 15.97% |
LoseDNA / S&P DNA unavailable / 42.23% |
| 2021-Q40/3 |
LoseDNA / S&P -28.30% / 11.03% |
LoseDNA / S&P DNA unavailable / 15.00% |
LoseDNA / S&P DNA unavailable / 96.40% |
| 2021-Q31/3 |
WinDNA / S&P 16.37% / 0.58% |
LoseDNA / S&P DNA unavailable / 10.77% |
LoseDNA / S&P DNA unavailable / 69.42% |
| 2021-Q20/3 |
LoseDNA / S&P DNA unavailable / 8.55% |
LoseDNA / S&P DNA unavailable / 6.58% |
LoseDNA / S&P DNA unavailable / 51.81% |
| 2021-Q10/3 |
LoseDNA / S&P DNA unavailable / 6.17% |
LoseDNA / S&P DNA unavailable / -1.06% |
LoseDNA / S&P DNA unavailable / 7.39% |
| 2020-Q40/3 |
LoseDNA / S&P DNA unavailable / 12.15% |
LoseDNA / S&P DNA unavailable / -3.72% |
LoseDNA / S&P DNA unavailable / -33.42% |
| 2020-Q30/3 |
LoseDNA / S&P DNA unavailable / 8.93% |
LoseDNA / S&P DNA unavailable / -2.04% |
LoseDNA / S&P DNA unavailable / -27.10% |
| 2020-Q20/3 |
LoseDNA / S&P DNA unavailable / 20.54% |
LoseDNA / S&P DNA unavailable / -0.46% |
LoseDNA / S&P DNA unavailable / -27.11% |
| 2020-Q10/3 |
LoseDNA / S&P DNA unavailable / -19.60% |
LoseDNA / S&P DNA unavailable / 3.47% |
LoseDNA / S&P DNA unavailable / -14.75% |
| 2019-Q40/3 |
LoseDNA / S&P DNA unavailable / 9.07% |
LoseDNA / S&P DNA unavailable / 5.36% |
LoseDNA / S&P DNA unavailable / 2.99% |
| 2019-Q30/3 |
LoseDNA / S&P DNA unavailable / 1.70% |
LoseDNA / S&P DNA unavailable / 5.02% |
LoseDNA / S&P DNA unavailable / 0.21% |
| 2019-Q20/3 |
LoseDNA / S&P DNA unavailable / 4.30% |
LoseDNA / S&P DNA unavailable / 6.64% |
LoseDNA / S&P DNA unavailable / 8.65% |
| 2019-Q10/3 |
LoseDNA / S&P DNA unavailable / 13.65% |
LoseDNA / S&P DNA unavailable / 8.12% |
LoseDNA / S&P DNA unavailable / 14.29% |
| 2018-Q40/3 |
LoseDNA / S&P DNA unavailable / -13.52% |
LoseDNA / S&P DNA unavailable / 9.05% |
LoseDNA / S&P DNA unavailable / 18.23% |
| 2018-Q30/3 |
LoseDNA / S&P DNA unavailable / 7.71% |
LoseDNA / S&P DNA unavailable / 10.21% |
LoseDNA / S&P DNA unavailable / 19.06% |
| 2018-Q20/3 |
LoseDNA / S&P DNA unavailable / 3.43% |
LoseDNA / S&P DNA unavailable / 9.03% |
LoseDNA / S&P DNA unavailable / 14.46% |
| 2018-Q10/3 |
LoseDNA / S&P DNA unavailable / -0.76% |
LoseDNA / S&P DNA unavailable / 7.68% |
LoseDNA / S&P DNA unavailable / 12.46% |
| 2017-Q40/3 |
LoseDNA / S&P DNA unavailable / 6.64% |
LoseDNA / S&P DNA unavailable / 7.03% |
LoseDNA / S&P DNA unavailable / 13.82% |
| 2017-Q30/3 |
LoseDNA / S&P DNA unavailable / 4.48% |
LoseDNA / S&P DNA unavailable / 5.68% |
LoseDNA / S&P DNA unavailable / 17.57% |
| 2017-Q20/3 |
LoseDNA / S&P DNA unavailable / 3.09% |
LoseDNA / S&P DNA unavailable / 4.83% |
LoseDNA / S&P DNA unavailable / 17.74% |
| 2017-Q10/3 |
LoseDNA / S&P DNA unavailable / 6.07% |
LoseDNA / S&P DNA unavailable / 3.67% |
LoseDNA / S&P DNA unavailable / 13.32% |
| 2016-Q40/3 |
LoseDNA / S&P DNA unavailable / 3.82% |
LoseDNA / S&P DNA unavailable / 2.09% |
LoseDNA / S&P DNA unavailable / 7.05% |
| 2016-Q30/3 |
LoseDNA / S&P DNA unavailable / 3.85% |
LoseDNA / S&P DNA unavailable / 0.20% |
LoseDNA / S&P DNA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | DNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -42.70% | 20.78% |
| Annualized return | -42.70% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | DNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.18% | 83.14% |
| Annualized return | -55.12% | 12.86% |
10Y · 2021-04-19 to 2026-08-27
| Metric | DNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.21% | 319.30% |
| Annualized return | -33.11% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.